Repositioning HDAC inhibitors for glioma treatment: synthesis and biological evaluation (2026)
Source: ACS Omega. Unidades: FCF, ICB
Subjects: FARMACOLOGIA, GLIOMA, NEOPLASIAS CEREBRAIS, FÁRMACOS (SISTEMA NERVOSO CENTRAL), RADIOTERAPIA, QUIMIOTERAPIA, ATIVAÇÃO ENZIMÁTICA, CÉLULAS CULTIVADAS DE TUMOR, APOPTOSE, CICLO CELULAR
ABNT
FURTADO, Luciana Costa et al. Repositioning HDAC inhibitors for glioma treatment: synthesis and biological evaluation. ACS Omega, v. 11, p. 10104-10120, 2026Tradução . . Disponível em: https://doi.org/10.1021/acsomega.5c11083. Acesso em: 18 abr. 2026.APA
Furtado, L. C., Waitman, K. de B., Silva, N. A. T. F. da, Gouvea, L. M., Kronenberger, T., Toledo, M. F. Z. J., et al. (2026). Repositioning HDAC inhibitors for glioma treatment: synthesis and biological evaluation. ACS Omega, 11, 10104-10120. doi:10.1021/acsomega.5c11083NLM
Furtado LC, Waitman K de B, Silva NATF da, Gouvea LM, Kronenberger T, Toledo MFZJ, Ferreira EG, Machado Neto JA, Kruyt FAE, Parise Filho R, Costa-Lotufo LV. Repositioning HDAC inhibitors for glioma treatment: synthesis and biological evaluation [Internet]. ACS Omega. 2026 ; 11 10104-10120.[citado 2026 abr. 18 ] Available from: https://doi.org/10.1021/acsomega.5c11083Vancouver
Furtado LC, Waitman K de B, Silva NATF da, Gouvea LM, Kronenberger T, Toledo MFZJ, Ferreira EG, Machado Neto JA, Kruyt FAE, Parise Filho R, Costa-Lotufo LV. Repositioning HDAC inhibitors for glioma treatment: synthesis and biological evaluation [Internet]. ACS Omega. 2026 ; 11 10104-10120.[citado 2026 abr. 18 ] Available from: https://doi.org/10.1021/acsomega.5c11083
